Which company does Vemurafenib come from?

Vemurafenib (Vemurafenib) was jointly developed by Roche and Plexxikon and was approved by the US Food and Drug Administration (FDA) on August 17, 2011, under the responsibility of Hoffmann La Roche. Following the approval, Roche launched an extensive development program in partnership with Genentech.

Vemurafenib is approved to treat cancer patients with certain mutations in the BRAF gene, including Erdheim-Chester disease and melanoma that cannot be removed with surgery or has spread to other parts of the body. Vemurafenib is also being studied in the treatment of other types of cancer. Vemurafenib is a potent and highly selective inhibitor of mutant BRAF V600E. Inhibiting the kinase activity of BRAF blocks signaling from the mitogen-activated pathway (MAP) kinase pathway and blocks the proliferation of malignant cells harboring this specific mutation. The drug is inactive in wild-type BRAF cells, unlike other drugs such as sorafenib that block both wild-type and mutant BRAF.

Vemurafenib The original drug has been launched in China and has entered the scope of medical insurance. The price of 240mg*56 tablets per box may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.